EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metagenomic Sequencing Reveals Distinct Gut Microbiome Profiles in Therapy-Naïve de Novo Pediatric Inflammatory Bowel Disease

Eva Vermeer iD, Femke M Prins iD, Iwan J Hidding iD, Jasmijn Z Jagt iD, Robert de Jonge iD, Marc A Benninga iD, Ranko Gacesa iD, Rinse K Weersma iD, Nanne K H de Boer iD, Tim G J de Meij iD

Inflammatory Bowel Diseases · 01.02.2026 · 32 (2) · 207-219

DOI: 10.1093/ibd/izaf184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 12.09.2025. Verfasst von Eva Vermeer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Gastroenterology and Hepatology, Emma Children's Hospital, Amsterdam University Medical Centre, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Metagenomics, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Dutch Digestive Foundation (MLDS), Right on Time.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Microbiome studies reveal distinct microbial differences in inflammatory bowel disease (IBD), indicating its potential role in pathophysiology and as a noninvasive diagnostic biomarker. This study aims to profile the gut microbiome in children with IBD, compared to both healthy controls (HC) and controls with gastrointestinal symptoms (CGI), and to assess the potential of microbiome profiles as noninvasive diagnostic markers for de novo treatment-naïve pediatric IBD, and as early predictive markers for therapy response.

Methods

We analyzed baseline fecal samples and clinical data from 103 therapy-naïve children with IBD, 75 CGI, and 356 age and sex matched HC. Metagenomic sequencing was performed, and prediction models assessed diagnostic potential and prediction of induction therapy response at 3 months.

Results

Alpha diversity progressively decreased from HC to CGI (P < .001) and decreased even further in IBD patients (P = .0056). Beta diversity analysis showed significant clustering differences (P < .001, R2 = 0.045). Differential abundance analysis revealed 116 species differing between HC and IBD, and 30 species between CGI and IBD. Prediction models based on microbiome features accurately distinguished IBD from HC (area under the curve [AUC] = 0.96) and from CGI (AUC = 0.71). However, these models were outperformed by clinical features, such as fecal calprotectin. Microbiome-based prediction of response to induction therapy in general showed limited accuracy (AUC = 0.63), as well as for response to nutritional induction therapy (AUC = 0.67).

Conclusions

We observed profound gut microbiome differences between de novo, therapy-naïve pediatric IBD patients and controls. While microbiome profiles hold promise for improving diagnostic precision, their predictive value for therapy response seems limited.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeMetagenomicsInflammatory Bowel DiseasesHumansFemaleMaleChildFecesCase-Control StudiesAdolescentBiomarkersChild, Preschool

Stichwörter der Autor:innen

Crohn’s diseasegut microbiomepediatric inflammatory bowel diseaseshotgun metagenomicsulcerative colitis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Pediatric Gastroenterology and Hepatology, Emma Children's Hospital, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
  • Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
  • Amsterdam Reproduction & Development (AR&D) Research Institute, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
  • Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands.
  • Department of Cardiology, University Medical Centre Groningen, Groningen, The Netherlands.
  • Department of Laboratory Medicine, Amsterdam University Medical Centre, Amsterdam, The Netherlands.

ORCID-Profile: Eva Vermeer, Femke M Prins, Iwan J Hidding, Jasmijn Z Jagt, Robert de Jonge, Marc A Benninga, Ranko Gacesa, Rinse K Weersma, Nanne K H de Boer, Tim G J de Meij

Förderung

  • The Dutch Digestive Foundation (MLDS)
  • Right on Time

Zitieren

APA

Vermeer, E., Prins, F. M., Hidding, I. J., Jagt, J. Z., de Jonge, R., Benninga, M. A., Gacesa, R., Weersma, R. K., de Boer, N. K. H., & de Meij, T. G. J. (2026). Metagenomic Sequencing Reveals Distinct Gut Microbiome Profiles in Therapy-Naïve de Novo Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 32(2), 207-219. https://doi.org/10.1093/ibd/izaf184

Vancouver

Vermeer E, Prins FM, Hidding IJ, Jagt JZ, de Jonge R, Benninga MA, et al. Metagenomic Sequencing Reveals Distinct Gut Microbiome Profiles in Therapy-Naïve de Novo Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2026;32(2):207-219. doi:10.1093/ibd/izaf184

BibTeX
@article{Vermeer2026,
  author = {Vermeer, Eva and Prins, Femke M and Hidding, Iwan J and Jagt, Jasmijn Z and de Jonge, Robert and Benninga, Marc A and Gacesa, Ranko and Weersma, Rinse K and de Boer, Nanne K H and de Meij, Tim G J},
  title = {Metagenomic Sequencing Reveals Distinct Gut Microbiome Profiles in Therapy-Naïve de Novo Pediatric Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  volume = {32},
  number = {2},
  pages = {207--219},
  doi = {10.1093/ibd/izaf184}
}
Kostenlos starten →